Trial · NCT03645395
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting Toxicity | Up to 1 year | Safety Population included participants who received at least one dose of any study drug (either MT-3724, or lenalidomide). Part 2 was not initiated due to Sponsor's decision to terminate the trial. | participants | NUMBER |
| PRIMARY | Part 1 and 2: Number of Participants With Abnormal Laboratory Parameters | Up to 1 year | Safety Population. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | Participants | NUMBER |
| PRIMARY | Part 1 and 2: Number of Participants With Clinically Significant Physical Findings | Up to 1 year | Safety population. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | ||
| SECONDARY | Part 1 and 2: Plasma Concentrations of MT-3724 | Days 1,3 and 12 of treatment cycle (Each cycle is of 28 days); Up to 1 year | PK population included all participants who received at least one dose of MT-3724 and have at least one post-baseline PK assessment. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | Micrograms per milliliter | MEAN |
| SECONDARY | Part 1 and 2: Change From Baseline in B-cell Count | Up to 1 year | Pharmacodynamic (PD) Population included all participants who received at least one dose of MT-3724 and have at least one post-baseline PD assessment. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | Giga cells per liter | MEAN |
| SECONDARY | Part 1 and 2: Number of Participants With Anti-drug Antibody Titer When Treated With MT-3724 | Up to 1 year | Immunogenicity Population included all participants who received at least one dose of MT-3724 and have at least one post-baseline immunogenicity assessment. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | ||
| SECONDARY | Part 1 and 2: Number of Participants With Neutralizing Antibody (NAb) Titers When Treated With MT-3724 | Up to 1 year | Immunogenicity Population included all participants who received at least one dose of MT-3724 and have at least one post-baseline immunogenicity assessment. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | ||
| SECONDARY | Part 1 and 2: Number of Participants With Objective Response Rate (ORR) | Up to 1 year | Safety population. Part 2 was not initiated due to Sponsor's decision to terminate the trial. The rows presenting data for PR and CR are mutually exclusive. | participants | NUMBER |
| SECONDARY | Part 1 and 2: Duration of Response (DOR) | Up to 1 year | Safety population. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | ||
| SECONDARY | Part 1 and 2: Progression Free Survival (PFS) | Up to 1 year | Safety population. Part 2 was not initiated due to Sponsor's decision to terminate the trial. | ||
| SECONDARY | Part 1 and 2: Overall Survival (OS) | Up to 1 year | Safety population. Part 2 was not initiated due to Sponsor's decision to terminate the trial. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03645395/outcomes